These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15975097)

  • 1. Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in Type 1 diabetes mellitus: a clinical audit in a specialist service.
    Rodrigues IA; Reid HA; Ismail K; Amiel SA
    Diabet Med; 2005 Jul; 22(7):842-9. PubMed ID: 15975097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years.
    Linkeschova R; Raoul M; Bott U; Berger M; Spraul M
    Diabet Med; 2002 Sep; 19(9):746-51. PubMed ID: 12207811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L; Dicembrini I; Mannucci E
    Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the effectiveness of long-term insulin pump therapy using a combined goal of HbA
    Quirós C; Viñals C; Giménez M; Roca D; Conget I
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Nov; 66(9):534-539. PubMed ID: 31133475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the timing of insulin pump therapy initiation after type 1 diabetes onset have an impact on glycemic control?
    Shalitin S; Lahav-Ritte T; Lebenthal Y; Devries L; Phillip M
    Diabetes Technol Ther; 2012 May; 14(5):389-97. PubMed ID: 22283639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
    Lepore G; Bonfanti R; Bozzetto L; Di Blasi V; Girelli A; Grassi G; Iafusco D; Laviola L; Rabbone I; Schiaffini R; Bruttomesso D;
    Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):335-342. PubMed ID: 29428572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years.
    Jakisch BI; Wagner VM; Heidtmann B; Lepler R; Holterhus PM; Kapellen TM; Vogel C; Rosenbauer J; Holl RW;
    Diabet Med; 2008 Jan; 25(1):80-5. PubMed ID: 18199134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of continuous subcutaneous insulin infusion in Type 1 diabetes: a 2-year perspective using the established criteria for funding from a National Health Service.
    Giménez M; Conget I; Jansà M; Vidal M; Chiganer G; Levy I
    Diabet Med; 2007 Dec; 24(12):1419-23. PubMed ID: 17941861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous Subcutaneous Insulin Infusion in Adult Type 1 Diabetes Mellitus Patients: Results from a Public Health System.
    Moreno-Fernandez J; Gomez FJ; Pinés P; González J; López J; López LM; Blanco B; Roa C; Herranz S; Muñoz-Rodríguez JR
    Diabetes Technol Ther; 2019 Aug; 21(8):440-447. PubMed ID: 31199682
    [No Abstract]   [Full Text] [Related]  

  • 11. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
    Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
    BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HbA
    Evans-Cheung TC; Campbell F; Yong J; Parslow RC; Feltbower RG
    Diabet Med; 2019 Jan; 36(1):88-95. PubMed ID: 30059173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life.
    Bruttomesso D; Pianta A; Crazzolara D; Scaldaferri E; Lora L; Guarneri G; Mongillo A; Gennaro R; Miola M; Moretti M; Confortin L; Beltramello GP; Pais M; Baritussio A; Casiglia E; Tiengo A
    Diabet Med; 2002 Aug; 19(8):628-34. PubMed ID: 12147142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained benefits of continuous subcutaneous insulin infusion.
    Hughes CR; McDowell N; Cody D; Costigan C
    Arch Dis Child; 2012 Mar; 97(3):245-7. PubMed ID: 21109506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland.
    Jeyam A; Gibb FW; McKnight JA; Kennon B; O'Reilly JE; Caparrotta TM; Höhn A; McGurnaghan SJ; Blackbourn LAK; Hatam S; McCrimmon RJ; Leese G; Lindsay RS; Petrie J; Chalmers J; Philip S; Wild SH; Sattar N; McKeigue PM; Colhoun HM;
    Diabetologia; 2021 Jun; 64(6):1320-1331. PubMed ID: 33686483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report.
    Weinzimer SA; Ahern JH; Doyle EA; Vincent MR; Dziura J; Steffen AT; Tamborlane WV
    Pediatrics; 2004 Dec; 114(6):1601-5. PubMed ID: 15574621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy Outcomes and Insulin Requirements in Women with Type 1 Diabetes Treated with Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections: Cohort Study.
    Abell SK; Suen M; Pease A; Boyle JA; Soldatos G; Regan J; Wallace EM; Teede HJ
    Diabetes Technol Ther; 2017 May; 19(5):280-287. PubMed ID: 28282241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin Pump Combined with Flash Glucose Monitoring: A Therapeutic Option to Improve Glycemic Control in Severely Nonadherent Patients with Type 1 Diabetes.
    Halbron M; Bourron O; Andreelli F; Ciangura C; Jacqueminet S; Popelier M; Bosquet F; Rouanet S; Amouyal C; Hartemann A
    Diabetes Technol Ther; 2019 Jul; 21(7):409-412. PubMed ID: 31265349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Modality-Dependent Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes: Danish Adult Diabetes Database Study.
    Hoshina S; Andersen GS; Jørgensen ME; Ridderstråle M; Vistisen D; Andersen HU
    Diabetes Technol Ther; 2018 Mar; 20(3):229-234. PubMed ID: 29437465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
    Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
    Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.